Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 118
about
A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavirBoosted tipranavir versus darunavir in treatment-experienced patients: observational data from the randomized POTENT trial.Switch from enfuvirtide to raltegravir lowers plasma concentrations of darunavir and tipranavir: a pharmacokinetic substudy of the EASIER-ANRS 138 trial.HIV protease inhibitors: recent clinical trials and recommendations on use.Saquinavir, the pioneer antiretroviral protease inhibitor.Differences in implementation of HIV/AIDS clinical research in developed versus developing world: an evidence-based review on protease inhibitor use among women and minorities.Tipranavir: a novel protease inhibitor for HIV therapy
P2860
Q33899829-448B5BDE-6764-41EA-A6D0-EB47E7955585Q34050693-FFE9560A-1609-45D3-86C6-FF5DDFEEAC80Q35065925-F0A4C7F8-E360-45B8-A485-57C2C4FDDFC7Q37519715-298DD4E3-B0D4-4161-BED0-27064C24CBE3Q37593552-2228F95E-F0A3-4134-B726-F761B44404CDQ38069146-0778370E-6988-4377-8F9F-E29C50A893EFQ58388976-8529620B-DF70-41C2-945F-39CD296D8AFF
P2860
Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 118
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Pharmacokinetics, safety, and ...... rienced patients (BI Study 118
@en
Pharmacokinetics, safety, and ...... rienced patients (BI Study 118
@nl
type
label
Pharmacokinetics, safety, and ...... rienced patients (BI Study 118
@en
Pharmacokinetics, safety, and ...... rienced patients (BI Study 118
@nl
prefLabel
Pharmacokinetics, safety, and ...... rienced patients (BI Study 118
@en
Pharmacokinetics, safety, and ...... rienced patients (BI Study 118
@nl
P2093
P1476
Pharmacokinetics, safety, and ...... rienced patients (BI Study 118
@en
P2093
Gary Blick
Gerald Pierone
Johnathan G Leith
Keikawus Arestéh
Margaret Johnson
Sharon L Walmsley
Thomas R MacGregor
Ulrich Meier
P304
P356
10.1097/QAI.0B013E318160A529
P407
P577
2008-04-01T00:00:00Z